key: cord-0685027-1n79xuuz authors: Balushi, Asma Al; AlShekaili, Jalila; Kindi, Mahmood Al; Ansari, Zainab; Al-Khabori, Murtadha; Khamis, Faryal; Ambusaidi, Zaiyana; Balushi, Afra Al; Huraizi, Aisha Al; Sulaimi, Sumaiya Al; Fahdi, Fatma Al; Balushi, Iman Al; Pandak, Nenad; Fletcher, Tom; Nasr, Iman title: Immunological predictors of disease severity in patients with COVID-19 date: 2021-07-01 journal: Int J Infect Dis DOI: 10.1016/j.ijid.2021.06.056 sha: 9ffd21c599cedb2aa6c57f3fe08c240412ed51ee doc_id: 685027 cord_uid: 1n79xuuz BACKGROUND: : Identifying immune cells involved in COVID-19 disease progression and predictors of poor outcomes is important to manage patients adequately. METHODS: : A prospective observational cohort study enrolled 53 mild non-hospitalized and 48 hospitalized confirmed COVID-19 patients to a tertiary hospital in Oman. RESULTS: : Hospitalized patients were older (58 years vs 36 years, p <0.001) and had more comorbid conditions like diabetes (65 % Vs 21% p<0.001). Hospitalized patients had significantly higher inflammatory markers (p<0.001); C-reactive protein (CRP) (114 vs 4 mg/L), Interleukin-6 (IL-6) (33 vs 3.71pg/ml), lactate dehydrogenase (LDH) (417 vs 214 U/L), ferritin (760 vs 196 ng/mL), fibrinogen (6 vs 3 g/L), D-dimer (1.0 vs 0.3 mcg/mL), disseminated intravascular coagulopathy (DIC) score (2 vs 0) and neutrophil/lymphocyte ratio (4 vs 1.1), (p<0.001). In multivariate regression analysis, statistically significant independent early predictors of ICU admission or death were higher levels of IL-6 (OR 1.03, p=0.03), frequency of large inflammatory monocytes (CD14+CD16+) (OR 1.117, p=0.010) and frequency of circulating naïve CD4+ T cells (CD27+CD28+CD45RA+CCR7+) (OR 0.476, p=0.03). CONCLUSION: : IL-6, frequency of large inflammatory monocytes, and circulating naïve CD4 T cells can be used as independent immunological predictors of poor outcomes in COVID-19 patients to prioritize critical care and resources.  COVID-19 severity predictors help to prioritize resources and minimize mortality  Immunological markers can be used as predictors of poor prognosis  High IL-6 independently predicts poor outcomes in COVID-19 patients  High percentage of large inflammatory monocytes predicts worse COVID-19 outcomes  Lower circulating Naïve CD4+ T cells predicts poor prognosis in COVID-19 patients Abstract: Background: Identifying immune cells involved in COVID-19 disease progression and predictors of poor outcomes is important to manage patients adequately. Methods: A prospective observational cohort study enrolled 53 mild non-hospitalized and 48 hospitalized confirmed COVID-19 patients to a tertiary hospital in Oman. Results: Hospitalized patients were older (58 years vs 36 years, p <0.001) and had more comorbid conditions like diabetes (65 % Vs 21% p<0.001). Hospitalized patients had significantly higher inflammatory markers (p<0.001); C-reactive protein (CRP) (114 vs 4 mg/L), Interleukin-6 (IL-6) (33 vs 3.71pg/ml), lactate dehydrogenase (LDH) (417 vs 214 U/L), ferritin (760 vs 196 ng/mL), fibrinogen (6 vs 3 g/L), D-dimer (1.0 vs 0.3 mcg/mL), disseminated intravascular coagulopathy (DIC) score (2 vs 0) and neutrophil/lymphocyte ratio (4 vs 1.1), (p<0.001). In multivariate regression analysis, statistically significant independent early predictors of ICU admission or death were higher levels of IL-6 (OR 1.03, p=0.03), frequency of large inflammatory monocytes (CD14+CD16+) (OR 1.117, p=0.010 ) and frequency of circulating naïve CD4+ T cells (CD27+CD28+CD45RA+CCR7+) (OR 0.476, p=0.03) . Conclusion: IL-6, frequency of large inflammatory monocytes, and circulating naïve CD4 T cells can be used as independent immunological predictors of poor outcomes in COVID-19 patients to prioritize critical care and resources. COVID-19, lymphocyte subsets, Inflammatory markers, Immunological predictors, mortality predictors Introduction: novel coronavirus has been identified as the cause, named later as Severe Acute Respiratory Syndrome -2 (SARS-CoV-2) (Lai et al. 2020; Yu et al. 2020) . The World Health Organization (WHO) declared it a pandemic on 11 March 2020, with total confirmed cases exceeding 121 million cases worldwide and over 2.6 million deaths by 20 th March 2021 . Some people develop severe coronavirus disease 2019 (COVID-19) disease while others remain asymptomatic or have a milder illness course . Identifying predictors of poor outcomes is increasingly gaining importance to help to prioritize resources for high-risk patients and minimize death. Older age and certain comorbid conditions like chronic renal, lung, and heart diseases are established predictors of worse prognosis in COVID-19 patients. In addition, hypoxemia, diarrhea, and high inflammatory markers like C-reactive protein (CRP) and interleukin-6 (IL-6) on admission are also predictors of worse prognosis (Bhargava et al. 2020; Aziz et al. 2020; Shi et al. 2020; Prompetchara, Ketloy, and Palaga 2020). In these patients, immune cells, namely lymphocytes, have been heavily implicated in controlling disease progression and clinical outcomes. Some studies have demonstrated that higher leukocyte counts, specifically neutrophils Chen et al. 2010; Prompetchara, Ketloy, and Palaga 2020) , and T cell lymphopenia (CD3+, CD8+ Urra et al. 2020 ) and CD4 )) are associated with increased mortality in patients admitted with COVID-19 pneumonia. Moreover, it was shown that older patients have lower counts and frequency of naïve (CD45RA+CCR7+CD27+CD28+) CD4+T cell contributing to the poor response of T cells (Koch et al. 2008 ). These cells are required for the effective handling of new infections or vaccines (Pawelec 2018; Li, Manwani, and Leng 2011) . It has been already shown that hospitalized COVID-19 patients have reduced (CD45RA+CCR7+CD27+CD28+) CD4+ naïve subsets of T cells compared to healthy uninfected controls (De Biasi et al. 2020) . Furthermore, hospitalized patients with severe manifestations have a lower frequency of exhausted non-cytotoxic T cells (PD-1+ CD57-CD8+) (Kusnadi et al. 2021) . Monocytes are other immune cells that are also vital for normal and dysregulated immune response. Monocytopenia was found to be a predictor of worse outcomes in patients with severe community infections and sepsis (Aalto et al. 2007) . Moreover, there is a reduction in the classic monocytes (CD14+CD16-) in severe SARS-CoV-2 infection and an increase in the inflammatory subsets (CD14+CD16+) (Payen et al. 2020) . Monocytes were also recently divided based on size into small and large subsets, coupled with a level of CD14 and CD16 expression into different subsets with different functional abilities (Merah-Mourah et al. 2020 ). Our study aimed to identify changes in immune variables, namely naïve CD4+ and CD8+, (CD45RA+CCR7+ CD27+CD28+), exhausted T cells CD8+ (PD-1+ CD57-), large and small inflammatory (CD14+CD16+) monocytes, and IL-6 level early in the course of COVID -19 infection as immunological predictors of poor outcomes including ICU admission and death. This was a prospective observational cohort study conducted from 20 July 2020 to 27 August 2020. A total of 101 COVID-19 cases confirmed by SARS-CoV-2 real-time polymerase chain reaction (RT-PCR) from nasopharyngeal swabs were enrolled (53 non-hospitalized and 48 hospitalized cases). Inclusion criteria were: patients aged 13 years or older, both genders, confirmed mild SARS-CoV-2 infection in the non-hospitalized group, and confirmed moderate infection in patients hospitalized at the Royal Hospital (RH). Hospitalized patients were recruited within 48 hours of admission. Patients admitted directly to the ICU at the time of enrolment were excluded from the study. Mild cases were those who did not require admission to the hospital due to COVID-19 related illness or oxygen therapy. In contrast, moderate cases were identified as patients with hypoxemia + T cells Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths Frailty, inflammation, and immunity The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks Identification of Novel Human Monocyte Subsets and Evidence for Phenotypic Groups Defined by Interindividual Variations of Expression of Adhesion Molecules Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells Phenotypic classification of human CD4+ T cell subsets and their differentiation Age and immunity: What is "immunosenescence A Longitudinal Study of Immune Cells in Severe COVID-19 Patients Comparison of Monocyte Distribution Width (MDW) and Procalcitonin for early recognition of sepsis Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic Four Functionally Distinct Populations of Human Effector-Memory CD8+ T Lymphocytes Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan Differential Redistribution of Activated Monocyte and Dendritic Cell Subsets to the Lung Associates with Severity of COVID-19 COVID-19 infection: the perspectives on immune responses Immune dysfunction following COVID-19, especially in severe patients Selective CD8 cell reduction by SARS-CoV-2 is associated with a worse prognosis and systemic inflammation in COVID-19 patients Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis' Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan Gamma-glutamyl transferase (GGT), prothrombin time (PT), or activated partial thromboplastin time (aPTT)